Search Results - "METRO, Giulio"
-
1
Chemotherapy in Combination With Immune Checkpoint Inhibitors for the First-Line Treatment of Patients With Advanced Non-small Cell Lung Cancer: A Systematic Review and Literature-Based Meta-Analysis
Published in Frontiers in oncology (16-04-2019)“…Checkpoint inhibitors plus platinum-based chemotherapy have shown superiority compared to chemotherapy alone as first-line therapy in advanced non-small cell…”
Get full text
Journal Article -
2
Immune checkpoint inhibitors-associated pericardial disease: a systematic review of case reports
Published in Cancer Immunology, Immunotherapy (01-10-2021)“…Treatment with immune checkpoint inhibitors (ICIs) can be complicated by cardiovascular toxicity, including pericardial disease. To date, no prospective…”
Get full text
Journal Article -
3
Resistance to TKIs in EGFR-Mutated Non-Small Cell Lung Cancer: From Mechanisms to New Therapeutic Strategies
Published in Cancers (08-07-2022)“…Resistance to tyrosine kinase inhibitors (TKIs) of the epidermal growth factor receptor (EGFR) in advanced mutant Non-Small Cell Lung Cancer (NSCLC)…”
Get full text
Journal Article -
4
Therapeutic options targeting angiogenesis in nonsmall cell lung cancer
Published in European respiratory review (01-03-2014)“…There is a major unmet medical need for effective and well-tolerated treatment options for patients with advanced nonsmall cell lung cancer (NSCLC), in both…”
Get full text
Journal Article -
5
Correlations Between the Immune-related Adverse Events Spectrum and Efficacy of Anti-PD1 Immunotherapy in NSCLC Patients
Published in Clinical lung cancer (01-07-2019)“…Immune-related adverse events (irAEs) developed during immunotherapy with anti-PD-1 agents, could be a predictive surrogate marker of clinical benefit in…”
Get full text
Journal Article -
6
Targeting NTRK fusion in non-small cell lung cancer: rationale and clinical evidence
Published in Medical oncology (Northwood, London, England) (01-06-2017)“…In the era of personalized medicine, the identification of targetable genetic alterations represented a major step forward in anticancer therapy. NTRK…”
Get full text
Journal Article -
7
The expanding scenario of advanced non-small-cell lung cancer between emerging evidence and clinical tasks
Published in Drugs in Context (02-05-2023)“…This Editorial by De Giglio, Ricciuti and Metro introduces the series :…”
Get full text
Journal Article -
8
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy
Published in Journal for immunotherapy of cancer (01-04-2021)“…BackgroundSome concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors…”
Get full text
Journal Article -
9
A Podcast on Pre- or Perioperative Chemoimmunotherapy for Stage III Non-Small Cell Lung Cancer: Shared Agreement from the Thoracic Surgeon and Oncologist Perspectives
Published in Oncology and therapy (01-06-2024)“…Management of stage II–III non-small cell lung cancer (NSCLC) has been dramatically revolutionized by studies testing the addition of immunotherapy (IO) to…”
Get full text
Journal Article -
10
Optimizing the risk stratification of astrocytic tumors by applying the cIMPACT-NOW Update 3 signature: real-word single center experience
Published in Scientific reports (16-11-2023)“…Our work reports implementation of a useful genetic diagnosis for the clinical managment of patients with astrocytic tumors. We investigated 313 prospectively…”
Get full text
Journal Article -
11
Indoleamine 2,3-Dioxygenase 2 Immunohistochemical Expression in Resected Human Non-small Cell Lung Cancer: A Potential New Prognostic Tool
Published in Frontiers in immunology (27-05-2020)“…Indoleamine 2,3-dioxygenase 2 (IDO2) is an analog of the tryptophan degrading and immunomodulating enzyme indoleamine 2,3-dioxygenase 1 (IDO1). Although the…”
Get full text
Journal Article -
12
Beyond Crizotinib: A Systematic Review and Meta-Analysis of the Next-Generation ALK Inhibitors as First-Line Treatment for ALK-Translocated Lung Cancer
Published in Frontiers in oncology (14-06-2022)“…Background Second and third-generation ALK inhibitors (ALKIs) have been recently approved for ALK-translocated lung cancer treatment, improving - and expanding…”
Get full text
Journal Article -
13
Long Noncoding RNA SBF2-AS1 Is Critical for Tumorigenesis of Early-Stage Lung Adenocarcinoma
Published in Molecular therapy. Nucleic acids (07-06-2019)“…Emerging evidence demonstrates that long non-coding RNAs (lncRNAs) are deeply involved in the development of various cancers. This study identified that…”
Get full text
Journal Article -
14
Non-small-cell lung cancer: how to manage ALK-, ROS1- and NTRK-rearranged disease
Published in Drugs in Context (12-10-2022)“…Oncogene addiction in non-small-cell lung cancer (NSCLC) has profound diagnostic and therapeutic implications. ALK , ROS1 and NTRK rearrangements are found in…”
Get full text
Journal Article -
15
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient Care
Published in Clinical cancer research (01-04-2011)“…To analyze HER2 status in primary breast cancer (PBC) compared with correspondent metachronous metastases and to investigate whether BC phenotype may be…”
Get full text
Journal Article -
16
Non-small-cell lung cancer: how to manage RET-positive disease
Published in Drugs in Context (11-07-2022)“…Targeted therapy has dramatically changed the history and outcomes of oncogene-addicted non-small-cell lung cancer (NSCLC). RET rearrangements are typically…”
Get full text
Journal Article -
17
Real-World Treatment Patterns and Survival Outcome in Advanced Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small-Cell Lung Cancer Patients
Published in Frontiers in oncology (21-08-2020)“…Introduction: Survival of ALK-rearranged NSCLC patients has dramatically improved by the use of multiple ALK-tyrosine kinase inhibitors (ALK-TKI). However,…”
Get full text
Journal Article -
18
Osimertinib in patients with advanced epidermal growth factor receptor T790M mutation-positive non-small cell lung cancer: rationale, evidence and place in therapy
Published in Therapeutic Advances in Medical Oncology (01-06-2017)“…The identification of epidermal growth factor receptor (EGFR) mutations represented a fundamental step forward in the treatment of advanced non-small cell lung…”
Get full text
Book Review Journal Article -
19
RET Rearrangement as a Predictor of Unresponsiveness to Immunotherapy in Non-Small Cell Lung Cancer: Report of Two Cases with Review of the Literature
Published in Oncology and therapy (01-12-2020)“…Patients with epidermal growth factor receptor and anaplastic lymphoma kinase positive non-small cell lung cancer (NSCLC) generally respond poorly to treatment…”
Get full text
Journal Article -
20
CT-Guided Percutaneous Trans-scapular Lung Biopsy in the Diagnosis of Peripheral Pulmonary Lesion Nodules of the Superior Lobes Using Large Needles
Published in Cardiovascular and interventional radiology (01-02-2018)“…Purpose CT-guided percutaneous transthoracic lung needle biopsy (PLB) is an effective procedure for obtaining cyto-histological diagnoses of peripheral…”
Get full text
Journal Article